Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | METAP2 | P50579 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679409 | 0.85 | ALDH1A1 (0.63) | HTTLMNAMAPTALDH1A1 | |
| SCHEMBL4586668 | 0.84 | KMT2A (0.61) | HTTLMNAMAPTALDH1A1 | |
| SCHEMBL4586462 | 0.84 | ALDH1A1 (0.58) | HTTLMNAMAPTALDH1A1 | |
| SCHEMBL4585595 | 0.84 | HTT (0.61) | HTTLMNAMAPTALDH1A1 | |
| SCHEMBL4586925 | 0.84 | MAPT (0.56) | HTTLMNAMAPTALDH1A1 | |
| SCHEMBL4585958 | 0.84 | ALDH1A1 (0.60) | HTTLMNAMAPTALDH1A1 | |
| SCHEMBL4593857 | 0.84 | CYP1A2 (0.62) | HTTLMNAMAPTALDH1A1 | |
| SCHEMBL12356339 | 0.83 | MAPT (0.59) | HTTMAPTALDH1A1 | |
| SCHEMBL679014 | 0.83 | ALDH1A1 (0.54) | LMNAGAAMAPTALDH1A1 | |
| SCHEMBL4882682 | 0.83 | CHRNB2 (0.64) | HTTLMNANPC1TP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096848-A1 | N-(2-(1H-Pyrazol-1-yl)-phenyl)-9H-fluorene-1-carboxamide for example; treating proliferative diseases such as cancer, viral diseases, inflammatory bowel disease, rheumatoid arthritis, psoriasis; combination therapy with other known anticancer drugs | CYTOVIA INC. (CA) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096848-A1 | N-(2-(1H-Pyrazol-1-yl)-phenyl)-9H-fluorene-1-carboxamide for example; treating proliferative diseases such as cancer, viral diseases, inflammatory bowel disease, rheumatoid arthritis, psoriasis; combination therapy with other known anticancer drugs | CASP1, CASP9, CASP14 | HTT 3535/4885LMNA 1917/4885NPC1 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.